Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

USPSTF Lowers the Recommended Age for CRC Screenings, Mandating Insurance Coverage

May 18, 2021
By Audrey Sternberg
News
Article

Recommendations published in JAMA are set to change colorectal cancer screening guidance for all individuals in the United States.

An update to the U.S. Preventive Services Task Force (USPSTF) recommendations now indicate that screening for colorectal cancer (CRC) should begin at age 45 years for all patients regardless of baseline characteristics, according to guidelines published in JAMA.1

This is a follow-up to draft guidance that was issued in October 2020 amending the recommended age of screening from 50 to 45 years of age and will mandate insurance coverage of screening for CRC.

These efforts by the task force are in large part a reaction to the alarming rise in the incidence of young-onset CRC, which occurs in patients younger than 50 years of age. By 2040, this is projected to be the leading cause of cancer deaths in patients ages 20 to 49 years.

This increasing incidence has been documented since the 1990s, but the proportion of patients with young-onset disease has accelerated rapidly over the last 10 years, with 11% of colon cancers and 15% of rectal cancers occurring in patients under the age of 50 years in 2020 compared with just 5% and 9%, respectively, in 2010.

“Clearly the USPSTF recommendation to start screening at age 45 will not be enough to catch those young people who are being diagnosed, but we must take bold steps to translate the lowered age of beginning screening into meaningful decreases in CRC incidence and mortality,” Kimmie Ng, MD, MPH, director of the Young-Onset Colorectal Cancer Center at Dana-Farber Cancer Institute and author of an accompanying editorial, said in a press release.2,3 “Lowering the recommended age to initiate screening will make colorectal cancer screening available to millions more people in the United States, and hopefully many more lives will be saved by catching colorectal cancer earlier, as well as by preventing colorectal cancer.”

Age 45 was selected by the task force based on evidence that averting more early deaths was possible versus starting at age 50 with a relatively small increase in the number of complications from colonoscopy. Of note, the new recommendation does not change guidance regarding screening in older individuals, with patients aged 76 to 85 years recommended for selective screening only.

In the editorial, Ng and colleagues point out that screenings at age 45 will not be enough to catch all cases of early-onset CRC, as the rate of colon cancer shows the steepest increase in patients aged 20 to 29 years at 2% versus 1.3% in those 40 to 49 years. Corresponding rates in rectal cancer were 3.2% and 2.3%, respectively.

“We are now seeing patients even younger than 45—in their 20s and 30s—who are being diagnosed with this cancer and often at very late stages,” Ng said. “Clearly the USPSTF recommendation to start screening at age 45 will not be enough to catch those young people who are being diagnosed.”

With the prior recommendations, less than 70% of patients who were eligible for screening received the preventative benefit, with patients who are uninsured or underinsured, those with lower incomes, and racial and ethnic minorities being disproportionately underserved. CRC is a disease that disproportionately affects African Americans, as they have a 20% greater likelihood of developing the tumor and a 40% greater risk of dying from it. As such, Ng and colleagues said addressing these public health barriers will be necessary to raise screening adherence.

References

1. US Preventive Services Task Force. Screening for Colorectal CancerUS Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(19):1965-1977. doi:10.1001/jama.2021.6238

2. Ng K, May FP, Schrag D. US Preventive Services Task Force Recommendations for Colorectal Cancer ScreeningForty-Five Is the New Fifty. JAMA. 2021;325(19):1943-1945. doi:10.1001/jama.2021.4133

'45 is the new 50' as age for colorectal cancer screening is lowered. News release. Dana-Farber Cancer Institute. May 18, 2021. Accessed May 18, 2021. https://bit.ly/3bBK1DT

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
The pediatric care wing of the Jack & Sheryl Morris Cancer Center is intended to accommodate the physical and emotional needs of younger patients with cancer.
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Leadership of a new cancer center as part of JFK University Medical Center discuss how they can support frontline clinicians.
Related Content

Preoperative Counseling Increases Shared Decision-Making in CRC Surgery

Preoperative Counseling Increases Shared Decision-Making in CRC Surgery

Roman Fabbricatore
June 11th 2025
Article

Counseling received prior to colorectal surgery using 3-dimensional–printed anatomic models reduced mean anxiety scores vs conventional counseling.


Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of pharmacology Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.


The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.

Olanzapine May Prevent Radiation-Induced Nausea and Vomiting

Roman Fabbricatore
June 5th 2025
Article

The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


Emergent alteration patterns were similarly diverse across treatment arms in the phase 3 CodeBreaK 300 study.

Genomic Alterations May Cause Resistance to Sotorasib KRAS G12C+ CRC Combo

Russ Conroy
May 31st 2025
Article

Emergent alteration patterns were similarly diverse across treatment arms in the phase 3 CodeBreaK 300 study.


Nivolumab/Ipilimumab Sustain Benefit Vs Chemo or Nivolumab in MSI-H/dMMR CRC

Nivolumab/Ipilimumab Sustain Benefit Vs Chemo or Nivolumab in MSI-H/dMMR CRC

Jordyn Sava
May 31st 2025
Article

The median PFS was 54.1 months with nivolumab/ipilimumab vs 5.9 months with chemotherapy in patients with MSI-H/dMMR CRC.

Related Content

Preoperative Counseling Increases Shared Decision-Making in CRC Surgery

Preoperative Counseling Increases Shared Decision-Making in CRC Surgery

Roman Fabbricatore
June 11th 2025
Article

Counseling received prior to colorectal surgery using 3-dimensional–printed anatomic models reduced mean anxiety scores vs conventional counseling.


Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of pharmacology Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.


The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.

Olanzapine May Prevent Radiation-Induced Nausea and Vomiting

Roman Fabbricatore
June 5th 2025
Article

The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


Emergent alteration patterns were similarly diverse across treatment arms in the phase 3 CodeBreaK 300 study.

Genomic Alterations May Cause Resistance to Sotorasib KRAS G12C+ CRC Combo

Russ Conroy
May 31st 2025
Article

Emergent alteration patterns were similarly diverse across treatment arms in the phase 3 CodeBreaK 300 study.


Nivolumab/Ipilimumab Sustain Benefit Vs Chemo or Nivolumab in MSI-H/dMMR CRC

Nivolumab/Ipilimumab Sustain Benefit Vs Chemo or Nivolumab in MSI-H/dMMR CRC

Jordyn Sava
May 31st 2025
Article

The median PFS was 54.1 months with nivolumab/ipilimumab vs 5.9 months with chemotherapy in patients with MSI-H/dMMR CRC.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.